Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:LNTH NASDAQ:MLTX NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$190.35+4.2%$173.47$111.09▼$190.35$11.17B0.41437,234 shs1.01 million shsLNTHLantheus$54.86+5.8%$76.68$47.25▼$118.21$3.59B0.141.73 million shs3.90 million shsMLTXMoonLake Immunotherapeutics$51.89-1.6%$48.60$31.42▼$58.26$3.38B1.27537,532 shs296,159 shsROIVRoivant Sciences$11.55-0.9%$11.32$8.73▼$13.06$7.92B1.154.44 million shs4.64 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+4.24%+9.71%+13.19%+25.85%+53.98%LNTHLantheus+5.76%-22.94%-33.43%-32.98%-42.91%MLTXMoonLake Immunotherapeutics-1.65%+2.87%+10.99%+34.88%+20.51%ROIVRoivant Sciences-0.90%+1.67%+6.35%+8.45%+13.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S2.6253 of 5 stars3.52.00.00.03.11.70.6LNTHLantheus4.6129 of 5 stars3.43.00.04.23.02.51.9MLTXMoonLake Immunotherapeutics2.6829 of 5 stars4.40.00.00.03.12.50.0ROIVRoivant Sciences2.361 of 5 stars3.61.00.00.02.53.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$223.6717.50% UpsideLNTHLantheus 2.86Moderate Buy$114.50108.71% UpsideMLTXMoonLake Immunotherapeutics 2.78Moderate Buy$74.4343.44% UpsideROIVRoivant Sciences 3.25Buy$16.5042.86% UpsideCurrent Analyst Ratings BreakdownLatest MLTX, ASND, ROIV, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/7/2025LNTHLantheusJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$112.00 ➝ $73.008/7/2025LNTHLantheusMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$120.00 ➝ $70.008/6/2025MLTXMoonLake ImmunotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$74.00 ➝ $82.007/29/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$245.00 ➝ $254.007/28/2025MLTXMoonLake ImmunotherapeuticsRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold7/28/2025MLTXMoonLake ImmunotherapeuticsRothschild & Co RedburnSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$65.007/16/2025LNTHLantheusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform7/11/2025ASNDAscendis Pharma A/SCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$213.00 ➝ $243.007/10/2025ROIVRoivant SciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$19.007/3/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$250.006/23/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$122.00 ➝ $109.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M29.58N/AN/A($1.88) per share-101.25LNTHLantheus$1.53B2.47$7.50 per share7.31$16.86 per share3.25MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$5.59 per shareN/AROIVRoivant Sciences$29.05M270.26N/AN/A$7.45 per share1.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$6.28N/A793.13N/A-93.22%N/A-33.29%N/ALNTHLantheus$312.44M$3.5214.598.69N/A17.82%34.06%19.10%N/AMLTXMoonLake Immunotherapeutics-$118.94M-$2.78N/AN/AN/AN/A-40.98%-35.81%N/AROIVRoivant Sciences-$171.98M-$0.25N/AN/AN/A-225.71%-14.76%-13.69%8/11/2025 (Estimated)Latest MLTX, ASND, ROIV, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2026ROIVRoivant Sciences-$0.23N/AN/AN/A$6.92 millionN/A8/6/2025Q2 2025LNTHLantheus$1.65$1.57-$0.08$1.12$389.69 million$378.05 million8/5/2025Q2 2025MLTXMoonLake Immunotherapeutics-$0.73-$0.87-$0.14-$0.87N/AN/A5/29/2025Q4 2025ROIVRoivant Sciences-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million5/12/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76-$0.63+$0.13-$0.63N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.040.71LNTHLantheus0.494.295.46MLTXMoonLake Immunotherapeutics0.2116.6521.11ROIVRoivant SciencesN/A33.4733.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ALNTHLantheus99.06%MLTXMoonLake Immunotherapeutics93.85%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%LNTHLantheus1.50%MLTXMoonLake Immunotherapeutics12.02%ROIVRoivant Sciences10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.15 million36.69 millionOptionableLNTHLantheus70069.19 million68.15 millionOptionableMLTXMoonLake Immunotherapeutics264.01 million56.32 millionOptionableROIVRoivant Sciences860679.81 million606.39 millionOptionableMLTX, ASND, ROIV, and LNTH HeadlinesRecent News About These CompaniesAn Overview of Exact Sciences's EarningsAugust 5 at 11:53 AM | benzinga.comRoivant Sciences (ROIV) Projected to Post Earnings on MondayAugust 5 at 11:21 AM | marketbeat.comPrivium Fund Management B.V. Has $1.28 Million Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)August 3, 2025 | marketbeat.comXTX Topco Ltd Boosts Position in Roivant Sciences Ltd. (NASDAQ:ROIV)July 30, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Has $751,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)July 30, 2025 | marketbeat.comRoivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025July 28, 2025 | globenewswire.comGoldman Sachs Resumes Roivant Sciences (ROIV) Coverage with ‘Buy’ RatingJuly 25, 2025 | msn.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Sells 100,000 Shares of StockJuly 24, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker Sells 100,000 SharesJuly 24, 2025 | insidertrades.comNew York State Common Retirement Fund Sells 28,400 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)July 24, 2025 | marketbeat.comMutual of America Capital Management LLC Sells 142,139 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)July 20, 2025 | marketbeat.comCenterBook Partners LP Buys New Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)July 16, 2025 | marketbeat.comBank of New York Mellon Corp Has $40.36 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)July 15, 2025 | marketbeat.comRoivant Sciences Ltd. (ROIV) - Yahoo FinanceJuly 10, 2025 | finance.yahoo.comRoivant Sciences (NASDAQ:ROIV) Earns Buy Rating from Analysts at The Goldman Sachs GroupJuly 10, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Sees Unusually-High Trading Volume - Still a Buy?July 9, 2025 | marketbeat.comDAVENPORT & Co LLC Reduces Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)July 9, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Stock Position Decreased by New York State Teachers Retirement SystemJuly 9, 2025 | marketbeat.com'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 million in five monthsJune 28, 2025 | msn.comRoivant Sciences’ president Venker sells $1.15 million in sharesJune 26, 2025 | investing.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,145,000.00 in StockJune 25, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMLTX, ASND, ROIV, and LNTH Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$190.35 +7.75 (+4.24%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$194.24 +3.89 (+2.04%) As of 08/7/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Lantheus NASDAQ:LNTH$54.86 +2.99 (+5.76%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$54.96 +0.10 (+0.18%) As of 08/7/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.MoonLake Immunotherapeutics NASDAQ:MLTX$51.89 -0.87 (-1.65%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$52.20 +0.31 (+0.60%) As of 08/7/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Roivant Sciences NASDAQ:ROIV$11.55 -0.10 (-0.86%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$11.16 -0.39 (-3.33%) As of 08/7/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
